Capital Asset Advisory Services LLC Purchases Shares of 456 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)


Share on StockTwits

Capital Asset Advisory Services LLC bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 456 shares of the pharmaceutical company’s stock, valued at approximately $108,000.

Several other large investors also recently bought and sold shares of VRTX. Janus Henderson Group PLC lifted its position in shares of Vertex Pharmaceuticals by 119.2% in the 4th quarter. Janus Henderson Group PLC now owns 4,166,534 shares of the pharmaceutical company’s stock worth $984,704,000 after purchasing an additional 2,265,577 shares during the period. Alliancebernstein L.P. lifted its position in shares of Vertex Pharmaceuticals by 20.3% in the 4th quarter. Alliancebernstein L.P. now owns 7,941,761 shares of the pharmaceutical company’s stock worth $1,876,956,000 after purchasing an additional 1,342,210 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Vertex Pharmaceuticals by 381.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 598,446 shares of the pharmaceutical company’s stock worth $141,437,000 after purchasing an additional 474,130 shares during the period. UBS Asset Management Americas Inc. lifted its position in shares of Vertex Pharmaceuticals by 29.3% in the 4th quarter. UBS Asset Management Americas Inc. now owns 2,087,167 shares of the pharmaceutical company’s stock worth $493,281,000 after purchasing an additional 473,124 shares during the period. Finally, Swedbank purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth about $101,666,000. 92.17% of the stock is owned by hedge funds and other institutional investors.

Shares of VRTX stock opened at $212.72 on Thursday. The company has a 50 day moving average price of $213.50 and a 200-day moving average price of $226.85. Vertex Pharmaceuticals Incorporated has a 52 week low of $202.57 and a 52 week high of $306.08. The firm has a market capitalization of $55.30 billion, a PE ratio of 26.86, a P/E/G ratio of 1.25 and a beta of 0.79. The company has a quick ratio of 3.60, a current ratio of 3.72 and a debt-to-equity ratio of 0.07.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Sunday, January 31st. The pharmaceutical company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $2.59 by ($0.08). Vertex Pharmaceuticals had a return on equity of 28.55% and a net margin of 38.51%. The company had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same quarter in the prior year, the firm earned $1.70 earnings per share. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 8.5 earnings per share for the current year.

Several research firms have recently commented on VRTX. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 11th. Robert W. Baird raised shares of Vertex Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $220.00 to $252.00 in a research report on Monday, March 1st. Piper Sandler lifted their price target on shares of Vertex Pharmaceuticals from $307.00 to $347.00 and gave the company an “overweight” rating in a research report on Tuesday, February 2nd. HC Wainwright lowered their price target on shares of Vertex Pharmaceuticals from $315.00 to $275.00 and set a “buy” rating for the company in a research report on Tuesday, February 2nd. Finally, SVB Leerink lowered their price target on shares of Vertex Pharmaceuticals from $257.00 to $250.00 and set a “market perform” rating for the company in a research report on Tuesday, February 2nd. Four equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $293.13.

In related news, EVP Bastiano Sanna sold 1,686 shares of the business’s stock in a transaction that occurred on Thursday, February 11th. The shares were sold at an average price of $210.56, for a total transaction of $355,004.16. Following the completion of the sale, the executive vice president now directly owns 39,081 shares in the company, valued at $8,228,895.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Paul M. Silva sold 1,498 shares of the business’s stock in a transaction that occurred on Thursday, February 11th. The shares were sold at an average price of $210.57, for a total transaction of $315,433.86. Following the sale, the chief accounting officer now owns 24,073 shares of the company’s stock, valued at $5,069,051.61. The disclosure for this sale can be found here. Insiders sold 7,200 shares of company stock valued at $1,533,052 over the last quarter. Company insiders own 0.70% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene.

Read More: Monthly Dividend Stocks

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.